Dr. George Poulogiannis is a Reader in Cancer Metabolism and Precision Medicine and Head of the Signalling and Cancer Metabolism Laboratory at the Institute of Cancer Research, London. After earning his Ph.D. from the University of Cambridge, where he studied the genome abnormalities of colorectal cancer at the laboratory of Andrew Wyllie and Mark Arends, George joined for his postdoctoral work with the group of Lew Cantley at Harvard Medical School to study the signalling and metabolic networks that are associated with the activation of the PI3K/Akt/mTOR pathway. In 2014, he joined the faculty of ICR to lead the Signalling and Cancer Metabolism Laboratory, and the research focus of his group is to understand the biochemical basis of metabolic reprogramming underlying cancer growth and progression, with the ultimate goal of aiding diagnostic stratification and identifying novel targets for cancer prevention/therapy.
Dr. George Poulogiannis is a Reader in Cancer Metabolism and Precision Medicine and Head of the Signalling and Cancer Metabolism Laboratory at the Institute of Cancer Research, London. After earning his Ph.D. from the University of Cambridge, where he studied the genome abnormalities of colorectal cancer at the laboratory of Andrew Wyllie and Mark Arends, George joined for his postdoctoral work with the group of Lew Cantley at Harvard Medical School to study the signalling and metabolic networks that are associated with the activation of the PI3K/Akt/mTOR pathway. In 2014, he joined the faculty of ICR to lead the Signalling and Cancer Metabolism Laboratory, and the research focus of his group is to understand the biochemical basis of metabolic reprogramming underlying cancer growth and progression, with the ultimate goal of aiding diagnostic stratification and identifying novel targets for cancer prevention/therapy.